Evidence map›Paper›PMID 34541287›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2021

Cortical thickness across the lifespan in a Colombian cohort with autosomal-dominant Alzheimer's disease: A cross-sectional study.

Joshua T Fox-Fuller, Heirangi Torrico-Teave, Federico d'Oleire Uquillas, Kewei Chen, Yi Su, Yinghua Chen, Michael Brickhouse, Justin S Sanchez, Cinthya Aguero, Heidi I L Jacobs and 16 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Joshua T Fox-FullerDepartment of Psychological and Brain Sciences Boston University Boston Massachusetts USA.
Heirangi Torrico-TeaveDepartment of Psychiatry Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Federico d'Oleire UquillasDepartment of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Kewei ChenBanner Alzheimer's Institute Phoenix Arizona USA.
Yi SuBanner Alzheimer's Institute Phoenix Arizona USA.
Yinghua ChenBanner Alzheimer's Institute Phoenix Arizona USA.
Michael BrickhouseDepartment of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Justin S SanchezDepartment of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Cinthya AgueroMassGeneral Institute for Neurodegenerative Disease Charlestown Massachusetts USA.
Heidi I L JacobsDivision of Nuclear Medicine Department of Radiology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Olivia HamptonDepartment of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Edmarie Guzmán-VélezDepartment of Psychiatry Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Clara Vila-CastelarDepartment of Psychiatry Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Daniel C Aguirre-AcevedoGrupo de Neurociencas Universidad de Antioquia Medellín Antioquia Colombia.
Ana BaenaGrupo de Neurociencas Universidad de Antioquia Medellín Antioquia Colombia.
Arabiye ArtolaDepartment of Psychiatry Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Jairo MartinezDepartment of Psychiatry Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Celina F PluimDepartment of Psychological and Brain Sciences Boston University Boston Massachusetts USA.
Sergio AlvarezDepartment of Radiology Hospital Pablo Tobon Uribe Medellín Colombia.
Martin Ochoa-EscuderoDepartment of Radiology Hospital Pablo Tobon Uribe Medellín Colombia.
Eric M ReimanBanner Alzheimer's Institute Phoenix Arizona USA.
Reisa A SperlingDepartment of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Francisco LoperaGrupo de Neurociencas Universidad de Antioquia Medellín Antioquia Colombia.
Keith A JohnsonDivision of Nuclear Medicine Department of Radiology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Bradford C DickersonDepartment of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Yakeel T QuirozDepartment of Psychiatry Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.

Funding

Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI STEVEN E ARNOLD · 2019 to 2026
$36.5M
Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI GONZALEZ HERNANDEZ, GRACIELA · 2001 to 2020
$32.5M
Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI Nicholas Ashton · 2021 to 2026
$24.9M
Alzheimer's Prevention Initiative ADAD Colombia TrialR01AG055444 · NIA · BANNER HEALTH · PI LOPERA, FRANCISCO, REIMAN, ERIC MICHAEL · 2017 to 2022
$14.9M
Relationship between tau pathology and cognitive impairment in autosomal dominant Alzheimer's diseaseR01AG054671 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2017 to 2021
$3.8M
Memory network dysfunction as an early marker of preclinical Alzheimer's DiseaseDP5OD019833 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2014 to 2018
$2.3M
Aerobic fitness as a modifier of neurodegeneration and cognitive decline in preclinical Alzheimer's diseaseK23AG061276 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GUZMÁN-VÉLEZ, EDMARIE · 2019 to 2023
$881k
Working Memory in Preclinical Alzheimer's Disease: a Neuropsychological and Neuroimaging InvestigationF31AG062158 · NIA · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI FULLER, JOSHUA THOMAS · 2019 to 2021
$117k
NIA NIH HHS F31 AG062158NIA NIH HHS K23 AG061276NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG072980NIA NIH HHS R01 AG054671NIA NIH HHS R01 AG055444NIH HHS DP5 OD019833
6 · The paper itself

Abstract

introductionCortical thinning is a marker of neurodegeneration in Alzheimer's disease (AD). We investigated the age-related trajectory of cortical thickness across the lifespan (9-59 years) in a Colombian kindred with autosomal dominant AD (ADAD).

methodsTwo hundred eleven participants (105 presenilin-1 [

resultsUnimpaired carriers exhibited elevated cortical thickness compared to non-carriers, and thickness more negatively correlated with age and cognition in carriers relative to non-carriers. We found increased cortical thickness in child carriers, after which thickness steadied compared to non-carriers prior to a rapid reduction in the decade leading up to the expected age at cognitive impairment in carriers. DISCUSSION: Findings suggest that cortical thickness may fluctuate across the ADAD lifespan, from early-life increased thickness to atrophy proximal to clinical onset.

Indexed as

age‐relatedcortical thicknessfamilial Alzheimer's diseaselifespanpresenilin1trajectory

Identifiers

PMID34541287
PMCPMC8438687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.